Evidence map›Paper›PMID 22082286›Full record

ArticleFuture microbiology2011

Examining the requirements for nucleoporins by HIV-1.

Anne Monette, Nelly Panté, Andrew J Mouland

Abstract readComment
PubMed Publisher
In one paragraph

Article in Future microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Anne MonetteHIV-1 RNA Trafficking Laboratory, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, Montréal, Québec, H3T 1E2, Canada.
Nelly Panté
Andrew J Mouland
Jewish General Hospital · CAMcGill University · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A hallmark of HIV type 1 and other lentiviruses is their ability to infect and replicate in nondividing cells by commandeering host nuclear transport factors. During the early stages of infection, this is expected to permit the safe passage of viral preintegration complexes (PICs) through nuclear pores. Numerous nuclear transport factors have been identified as essential for HIV-1 infection by genome-wide small interfering RNA screens, and many of these are currently under investigation. Here, using knockdown studies, Matreyek and Engelman further characterize the importance of transportin-3 and nuclear pore complex component nucleoporin 153 for the early stages of HIV-1 infection and show that these two proteins operate synergistically. Also, as was previously observed for transportin-3, they show that the requirement of nucleoporin 153 for PIC nuclear entry is determined by the HIV-1 Capsid protein. The refinement of the list of key nuclear pore complex and transport proteins required for PIC entry, along with a better understanding of the specific mechanisms employed, will undoubtedly lead to the development of future antiretroviral therapies that will have the potential to block HIV-1 viral DNA integration.

Identifiers

PMID22082286
OpenAlexW2074003691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.